<DOC>
	<DOCNO>NCT01584648</DOCNO>
	<brief_summary>This two-arm , double-blinded , randomize , Phase III study compare dabrafenib ( GSK2118436 ) trametinib ( GSK1120212 ) combination therapy dabrafenib administer trametinib placebo ( dabrafenib monotherapy ) . Subjects histologically confirm cutaneous melanoma either Stage IIIC ( unresectable ) Stage IV , BRAF V600E/K mutation positive screen eligibility . Subjects prior systemic anti-cancer treatment advance metastatic set eligible although prior systemic treatment adjuvant setting allow . Approximately 340 subject randomize 1:1 ( combination therapy : dabrafenib monotherapy ) . Subjects stratify lactate dehydrogenase ( LDH ) level ( &gt; upper limit normal ( ULN ) versus less equal ULN ) BRAF mutation ( V600E versus V600K ) . The primary endpoint investigator-assessed , progression-free survival subject receive combination therapy compare receive dabrafenib monotherapy . Subjects follow overall survival ; crossover permit .</brief_summary>
	<brief_title>A Study Comparing Trametinib Dabrafenib Combination Therapy Dabrafenib Monotherapy Subjects With BRAF-mutant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Histologically confirm cutaneous melanoma either Stage IIIC ( unresectable ) Stage IV ( metastatic ) , determine BRAF V600E/K mutationpositive use bioMerieux ( bMx ) investigational use ( IUO ) THxID BRAF Assay ( IDE : G120011 ) . The assay conduct central reference laboratory . Subjects ocular mucosal melanoma eligible . The subject must radiologically measurable tumor The subject able carry daily life activity without significant difficulty ( ECOG performance status score 0 1 ) . Able swallow retain oral medication Sexually active subject must use acceptable method contraception course study Adequate organ system function blood count Prior treatment BRAF MEK inhibitor Prior systemic anticancer treatment Stage IIIC ( unresectable ) Stage IV ( metastatic ) melanoma . Prior systemic treatment adjuvant setting allow . ( Note : Ipilimumab treatment must end least 8 week prior randomization . ) The subject receive major surgery certain tyes cancer therapy 21 day start treatment Current use prohibit medication list protocol Left ventricular ejection fraction less low limit normal Uncontrolled blood pressurl History current evidence retinal vein occlusion central serous retinopathy Brain metastases unless previously treat surgery stereotactic radiosurgery disease stable least 12 week The subject pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Randomized study</keyword>
	<keyword>combination therapy</keyword>
	<keyword>BRAF inhibitor</keyword>
	<keyword>GSK1120212</keyword>
	<keyword>BRAF V600E/K mutation-positive cutaneous melanoma</keyword>
	<keyword>trametinib</keyword>
	<keyword>GSK2118436</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>Phase III</keyword>
	<keyword>dabrafenib</keyword>
</DOC>